Ian Dixon
Managing Director & FounderPhD, MBA, MAICD
Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.
Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.
Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.
Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.
Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).
He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.
Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd.
Jason Watson
Non-Executive Director, ChairLL.B, B. Comm
Mr Jason Watson has board and advisory experience acting with small and medium-sized enterprises, research institutes and listed companies in the life sciences and other sectors. In particular, he has assisted companies in developing, commercialising and transacting technologies through significant biotechnology licensing deals.
Jason is principal of Elementary Law, a legal practice based in Melbourne, Australia. His practice focuses on assisting clients to achieve the best outcomes for their patents and innovations, including through corporate fundraising, protection strategies, licensing and commercialisation. In this capacity, Jason has been recognised in the Intellectual Asset Magazine Patent 1000 independent list of The World’s 1000 Leading Patent Professionals.
Jason has expertise in relation to complex transactions, including establishing multi-party engagements, research and consultancy contracts and negotiating and implementing clinical trial, licensing, assignment, manufacturing, shareholding and other commercial arrangements.
Jason has a Bachelor of Laws with Honours and a Bachelor of Commerce.
Clarke Barlow
NON-EXECUTIVE DIRECTORB.Comm, MAICD
Clarke is a Financial Adviser and Capital Markets Specialist with over 20 years’ experience in the Financial Services Industry in Australia and the United Kingdom.
Clarke has experience in structuring, operations and risk management of institutional exotic derivatives in the United Kingdom with Morgan Stanley International Limited and has been a Derivatives Manager, responsible for establishing and managing derivatives trading desks for several Australian based stockbroking firms.
Clarke brings to Exopharm his extensive experience providing corporate advisory services for companies listed on the Australian Securities Exchange (ASX) across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resource industries, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, mergers and acquisitions, investor relations and capital markets advice.
Clarke also services institutional, wholesale and retail clients, advising on ASX investments, share portfolios, derivatives, and identification of early-stage opportunities across a variety of industries and sectors.
Clarke is a Founding Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange.
Clarke holds a Bachelor of Commerce degree from the University of Western Australia and is a Member of the Australian Institute of Company Directors (AICD).
David Franks
Company SecretaryB.Ec, CA, F Fin, FGIA, JP.
David Franks is a Principal of the Automic Group. He is a Chartered Accountant, Fellow of the Financial Services Institute of Australia, Fellow of the Governance Institute of Australia, Justice of the Peace, Registered Tax Agent and holds a Bachelor of Economics (Finance and Accounting) from Macquarie University.
With over 20 years’ experience in finance, governance and accounting, David has been CFO, Company Secretary and/or Director for numerous ASX listed and unlisted public and private companies, in a range of industries covering biotech, energy retailing, transport, financial services, mineral exploration, technology, automotive, software development and healthcare.